Posted inHealthcare

Medicare’s Drug Price Negotiation Choices Risk Increasing, Not Decreasing, Spending

The Centers for Medicare & Medicaid Services just announced the next 15 brand-name medicines selected for Medicare’s drug price negotiation program, which mandates price reductions of at least 25 percent. Most Americans naturally assume that medicines will become more affordable as a result. Because two of the chronic-disease medicines selected — Orencia and Xolair — […]